BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Oct 08, 2001
 |  BioCentury  |  Emerging Company Profile

Graffinity: Fishing in another pond

While there are sophisticated high throughput methods to assess the role of novel genes and proteins in biological pathways, the chemistry side of the drug development equation is still looking bleak. The sheer number of possible compounds is overwhelming, and even if this chemical space is broken down to molecules obeying the "rule of five" describing the physico-chemical properties most drugs have in common, the number of candidates is beyond reasonable testing.

"So we chose to simply fish in another pond," said Dirk Vetter, president and one of the founders of Graffinity Pharmaceutical Design GmbH. "And we are trying to hook the targets with chemical microarrays."

By doing so, Graffinity hopes to bring chemistry to bear earlier in the drug discovery process so that one or two years can be cut off of the development timeline. "Our vision is to deliver to our partners for the early preclinical steps small molecules that are as selective and efficient as antibodies," said Vetter.

"The idea to...

Read the full 797 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >